So what are ATMPs exactly and why all the fuss about these therapies and the impact they are having within the market? Inbeeo hosted a free to attend webinar looking into this topic focusing on some specific country challenges within the US and EU, with 60+ attendees contributing to the discussion during the Q&A.
The Challenge Inbeeo’s client, a specialty CNS company, is preparing for the launch of their novel product in a highly competitive indication. There had been extensive
The Challenge Inbeeo’s client was a small clinical stage pharmaceutical company that was developing a novel product to treat Idiopathic Pulmonary Fibrosis (IPF), who were
The Challenge Inbeeo’s client, a specialty pharmaceutical company, is commercializing a novel radiopharmaceutical for an orphan oncology indication in Japan. Pricing mechanisms in Japan presented
The Challenge Inbeeo’s client, a global specialty company, was actively preparing for the launch of a Long-Acting Injectable form of their block-buster short-acting oral equivalent.
The Challenge In advance of an upcoming indication expansion for their advanced oncology product, Inbeeo’s client needed to understand the potential implications on HTA, pricing
French lawmakers are setting the scene for a showdown with manufacturers defending their drug prices with R&D investment figures.
